News | April 28, 2015

"Motion-Tracking" MRI Tests Reveal Novel Harbingers of Stroke in Atrial Fibrillation Patients

Johns Hopkins study finds that altered left atrium function could indicate higher risk for those with and without AFib

Johns Hopkins, motion-tracking MRI, stroke risk, atrial fibrillation

April 28, 2015 — Researchers from Johns Hopkins performing sophisticated motion studies of heart magnetic resonance imaging (MRI) scans have found that specific altered function in the left atrium may signal stroke risk in those with atrial fibrillation and those without it.

Stroke is a frequent and dreaded complication of atrial fibrillation (afib). But predicting which of the estimated six million Americans with afib are at highest risk has long challenged physicians weighing stroke risk against the serious side effects posed by lifelong therapy with warfarin and other blood thinners.

The new imaging technique combines standard MRI scans with a motion-tracking software that analyzes cardiac muscle movement.

Reporting April 27th in the Journal of the American Heart Association, researchers said the specialized tests can pave the way to more accurate risk-gauging models and more precise therapy among with highest likelihood of stroke. The current risk-assessment guidelines underestimate that risk in about 12 percent of people with afib who would benefit from prophylactic treatment with blood thinners, researchers said. At the same time, researchers added, averting overtreatment in lower-risk patients would prevent the rare but often-devastating brain bleeds that occur as a side effect of blood-thinners.

The study results, the research teams said, also cast doubt on the current clinical dogma that chaotic beating of the upper chambers of the heart during Am12trial fibrillation fuels the blood clot formation that causes stroke. That view, the team said, has failed to explain why many people with atrial fibrillation never have strokes and why many with history of atrial fibrillation have no evidence of abnormal rhythms within a month before the stroke.

“Our research suggests that certain features of the heart’s upper left chamber that are easily seen on heart MRI could be the smoking gun we need to tell apart low-risk from high-risk patients,” said lead investigator and heart rhythm specialist Hiroshi Ashikaga, M.D., Ph.D., assistant professor of medicine and biomedical engineering at the Johns Hopkins University School of Medicine.

The investigators said just how the suppressed function and altered anatomy of the left atrium cause stroke remains unclear, but said they have reason to believe these features reflect more sluggish blood flow that leads to clot formation and precipitates stroke.

“Our observations suggest that altered function in the left atrium of the heart may lead to stroke independently of the heart rhythm disturbance itself,” said co-investigator Joao Lima, M.D., professor of medicine and radiology at the Johns Hopkins University School of Medicine and director of cardiovascular imaging at The Johns Hopkins Hospital. “What this means is that people with compromised function in the left upper portion of the heart may be at risk for stroke, with or without atrial fibrillation.”

“Maybe when it comes to stroke risk and afib, we’ve been chasing the wrong guy all along,” Ashikaga said. “Maybe atrial fibrillation itself is not the real culprit and dysfunction of the left atrium is the real baddie. It’s a possibility we have to consider and will in an upcoming study.”

The new findings are based on analysis of records of 169 Johns Hopkins patients, ages 49 to 69, with atrial fibrillation who had cardiac MRIs before undergoing a minimally invasive procedure to burn off — or ablate — small sections of heart tissue that trigger the aberrant rhythm. Eighteen of the patients had suffered minor or major strokes prior to their ablations.

Using the enhanced motion imaging, the investigators compared images of the hearts of patients who had suffered strokes with those who had not, noticing several marked differences.

First, the left atria of patients who’d had strokes had notably reduced ability to empty out blood into the lower portion of the heart, an average of 35 percent per minute in patients with strokes, compared with 46 percent among those without strokes. In addition, the left atria were bigger and more dilated in patients who’d suffered strokes, an average volume of 52 milliliters per meter squared in stroke patients, compared with 44 in those without stroke. Finally, the left atria of patients who’d suffered strokes had worse overall ability to stretch out and recoil with each heartbeat, meaning that the heart muscle in this area of the heart was not as elastic and as capable of accommodating strain. Taken together, the researchers say, these features indicate that patients who’d suffered strokes had suppressed function and slower blood turnover in this portion of their heart muscle.

The research team is next planning to test the predictive value of this imaging approach in patients with and without atrial fibrillation, follow them closely and track their stroke risk over time.

For more information: www.hopkinsmedicine.org

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution
News | Magnetic Resonance Imaging (MRI) | July 05, 2019
Medic Vision Imaging Solutions announced that its 3-D iterative image reconstruction technology for shortening magnetic...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...